Eli Lilly and Company $LLY Shares Sold by iA Global Asset Management Inc.

iA Global Asset Management Inc. reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.9% in the second quarter, Holdings Channel.com reports. The institutional investor owned 23,564 shares of the company’s stock after selling 966 shares during the period. iA Global Asset Management Inc.’s holdings in Eli Lilly and Company were worth $18,369,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in LLY. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company during the 1st quarter worth $27,000. Blume Capital Management Inc. grew its stake in Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after buying an additional 14 shares during the last quarter. IMG Wealth Management Inc. bought a new position in Eli Lilly and Company during the 2nd quarter worth $35,000. Financial Gravity Asset Management Inc. bought a new position in Eli Lilly and Company during the 1st quarter worth $40,000. Finally, TD Capital Management LLC grew its stake in Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. Leerink Partners restated a “market perform” rating and set a $715.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 7th. BMO Capital Markets upped their price objective on Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a research note on Monday, October 20th. UBS Group decreased their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, Morgan Stanley decreased their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating for the company in a research note on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $940.00.

Eli Lilly and Company Trading Up 2.2%

NYSE:LLY opened at $862.96 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $935.63. The firm has a market capitalization of $816.76 billion, a price-to-earnings ratio of 56.40, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47. The stock has a fifty day simple moving average of $780.74 and a 200 day simple moving average of $771.71.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. During the same quarter last year, the company posted $1.18 EPS. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 39.22%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky acquired 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the purchase, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders bought 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.